Skip to content
Screener

PTC Therapeutics PTCT Q4 2025 Annual earnings

Reported February 19, 2026 · After market close

Revenue$164.7MMiss by $114.8M
EPS-$1.67Miss by $1.46
Revenue estimate$279.5M
EPS estimate-$0.21

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$303.9M
EPS estimate$0.29

Financials

Q4 2025

Income statement

See full
Revenue$164.7M-22.7%
Operating income-+100%

Balance sheet

See full
Cash & equivalents$984.6M+26.3%
Total debt$398.7M+1.6%
Total equity-$205.3M+81.3%
Total assets$2.9B+70.0%

Cash flow

See full
CapEx$2.4M-37.0%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$6.1B+75.2%
Enterprise value$5.51B+78.2%
P/S3.5×-0.8×

Profitability

See full
Operating margin54.2%+38.5pp

Returns & leverage

See full
Current ratio2.3×0.0×

Segments

By product

See full
Sephience$91.6M—
Translarna1$58.8M—
Emflaza$27.1M—
Other Products$6.0M—
Translarna-$294.9M—

By segment

See full
Life Science$164.7M-22.7%

FAQ

When did PTC Therapeutics report Q4 2025 earnings?
PTC Therapeutics (PTCT) reported Q4 2025 earnings on February 19, 2026 after market close.
What were PTC Therapeutics's Q4 2025 revenue and EPS?
PTC Therapeutics reported revenue of $164.7M and eps of $-1.67 for Q4 2025.
Did PTC Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $279.5M by $114.8M. EPS missed the consensus estimate of $-0.21 by $1.46.
How did PTC Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 22.7% from $213.2M a year earlier and eps declined 595.8% from $-0.24.
Where can I find PTC Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001104659-26-017546) and the 10-K periodic report (0001104659-26-017575) directly on SEC EDGAR. The filing index links above go to sec.gov.